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Background.The features of the portal hypertension enteropathy (PHE) vary frommild mucosal changes to varices with or without
bleeding.The prevalence and the development are not fully understood.Aim.Our aim is to examine the prevalence and the different
manifestations of PHE using video capsule endoscopy (VCE). Methods. It is a single center retrospective study of patients with
cirrhosis, who had VCE. Based on the published literature, we divided the PHE lesions into vascular lesions and mucosal lesions.
Results.Of the 100 patients with cirrhosis that had a VCE study, themean age was 62.82 years. Male gender was predominant (64%),
while Caucasians represented 82% of the cohort. The most common etiology of cirrhosis was chronic alcohol abuse followed by
chronic hepatitis C virus andnonalcoholic steatohepatitis. VCEdetected small bowel lesions in 71%of the patientswhile the features
of PHE were found in 65% from the total cohort. AVMs and inflammatory changes were the most common findings, followed by
bleeding. More than 50% of the lesions were vascular in nature.The risk of finding PHE in decompensated cirrhosis is twice that in
compensated cirrhosis. Forty-five patients had negative EGD exam for any active bleeding, esophageal varices, portal hypertensive
gastropathy, or gastric varices. Of these, 69% had features of PHE in their VCE. Conclusions. VCE detected small bowel lesions in
71% of our cohort. There is a high prevalence of PHE in decompensated cirrhosis. Vascular lesions are the most common finding
in the small bowel of this population.
1. Introduction
Cirrhosis or end-stage liver disease is defined as a late stage
of scarring and fibrosis of the liver and characterized by alter-
ation of the hepatic architecture as well as the development
of regenerative nodules; these changes can lead to amultitude
of complications. Cirrhosis can bemost commonly attributed
to excessive alcohol consumption, viral hepatitis, or nonalco-
holic fatty liver disease [1]. Reports from the Centers for Dis-
ease Control (CDC) estimate that 75,766 deaths and 2.3 mil-
lion years of potential life lost during 2001 were attributable
to excessive alcohol abuse, which also contributed to 60-70%
of the cirrhosis in the USA. It is the 12th leading cause of death
in USA and it is the leading cause of morbidity [2]. A recent
population-based study showed that, per 2-year interval, cir-
rhotic patients have 26.4%mortality rate as compared to pro-
pensitymatched controlswhohad amortality rate of 8.4% [3].
The pathophysiology behind developing portal hyper-
tension (PH) is believed to be related to scarring in the
liver parenchymal disease, the increased production of vaso-
constrictor (endothelins, angiotensin II, norepinephrine, and
thromboxane A2), and a decrease in secretion of endothelial
vasodilators. As a result, dysregulation of the extrahepatic
vascular beds occurs in the splanchnic and systemic circula-
tions causing the blood flow inside the portal veins to increase
and the portal vein pressure to rise. Approximately 50%of the
patients develop esophageal varices while a small percentage
develops complications in the other part of the gastrointesti-
nal tract like ectopic varices in the small bowel [4, 5].
With the availability of VCE in the last two decades, the
evaluation of the small bowel has become easy. The ramifica-
tions of PH in the small bowel are referred to as portal hyper-
tensive enteropathy (PHE). Multiple studies have attempted
to define PHE and identify the major components that it
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encompasses. Originally in 2005, De Palma et al. had noted
that PHE included mucosal inflammatory changes such as
edema, erythema, granularity, friability, and spontaneous
bleeding as well as vascular lesions such as cherry red spots,
telangiectasias, angiodysplasia, and varices [6]. Later in 2008,
Kodama et al. used double balloon enteroscopy to classify
PHE into villous lesions and vascular lesions [7]. Despite the
classifications, there is no gold standard scoring system to dif-
ferentiate the severity of endoscopic abnormalities found [8].
With the current definitions as stated above, the preva-
lence of PHE has been noted to vary between 18% and 100%
in patients with cirrhosis. The majority of data, when using a
broad definition of PHE, indicates that prevalence is >60%.
However, not all patients with cirrhosis have PHE; but there
are several risk factors that increase the likelihood of PHE:
CTP B and C, portosystemic shunts, ascites, portal thrombo-
sis, esophageal varices, and portal hypertensive gastropathy
[6, 9].
These patients are at a high risk of GI bleeding, especially
small intestinal bleeding that cannot be identified by EGD
and colonoscopies. Video capsule endoscopy has been used
more frequently in the last decade to identify the bleeding
source. VCE serves as the roadmap to allow for further inter-
ventions that need to be taken to evaluate and treat gastroin-
testinal bleeding.
2. Materials and Methods
We retrospectively reviewed the medical record of 100 con-
secutive patients who were found to be cirrhotic and to
have complete video capsule studies between 2010 and 2016
at the University of Massachusetts, UMass Medical Center.
Approval was obtained from the University of Massachusetts
Institutional Review Board (IRB). By using the ICD codes of
cirrhosis and the procedure code of the video capsule endo-
scope, we were able to identify our patient’s cohort. The chart
of each patient was reviewed, and the extracted data included
the general demographic features of the cohort: the age, gen-
der, and the race of the patients.Thediagnosis of cirrhosis was
made by histological findings or compatible typical radio-
graphic features, clinical presentations, and laboratory tests.
The severity of cirrhosis was classified using two classifica-
tions: Child-Pugh classification and the model for end-stage
liver disease (MELD) score classification.
Two generations of Given Imaging capsules were used
during the study period including the consecutive genera-
tions of PillCam SB2 and SB3 (Medtronic,Minneapolis,MN).
Reading software was Rapid v 6-8. Video capsule endoscopy
studies were read by experienced gastroenterologists and the
findings were documented in in Provation (Provation, Min-
neapolis, MN). The findings used in this study included the
indications for the video capsule evaluation as documented in
the charts of the patients which were obscure GI bleed, ane-
mia, and/or abnormal findings on the cross-sectional imag-
ing studies.
3. Classification
Our classification of the PHE was based on the published
studies reported by De Palma et al., Kodama et al., and
Abdelaal et al. [6, 7, 10].The first classification of the PHEwas
reported byDe Palma et al. in 2005.We divided PHE into two
grades: Grade 1 which includes edema, erythema, granularity,
friability, and/or spontaneous bleeding andGrade 2 which in-
cludes cherry-red spots, telangiectasias, angiodysplasia-like
lesions, and varices.
Kodama et al. divided PHE into villous lesions and vascu-
lar lesions. Villous lesions include either edema, atrophy, or
erythematous changes of the villi while vascular lesions in-
clude varices, red spots, vascular spiders, and lymphoid fol-
licles with dilated vessels and dilated/proliferated vessels.
Lastly, Abdelaal et al. diagnosed PHE based on his scoring
system which depended on four main types of mucosal le-
sions of the small intestine: red spots, angioectasias, varices,
and inflammatory-like lesions.
In our study, we divided the PHE lesions into two types
of lesions: vascular and mucosal lesions. Vascular lesions in-
cluded arteriovenous malformation (AVM), red spots, bleed-
ing, or varices while the mucosal lesions included mild in-
flammatory changes such as erythematous changes and ede-
ma or severe inflammatory changes including mosaic-like
pattern or snakeskin mucosal changes, and congested and fri-
able mucosa.
We also divided our cohort based on their Child-Tur-
cotte-Pugh (CTP) classification into classes A, B, and C using
the patients’ clinical presentations of ascites and hepatic ence-
phalopathy, in addition to their laboratory findings.
4. Statistical Analysis
Comparisons were performed using the unpaired chi-square
test for quantitative data and the chi-squared test for categor-
ical data. A Yates correction or Fisher’s exact test was used
when required. P-value< 0.05 was considered statistically
significant. Odds ratios (ORs) and 95% confidence intervals
(95% CIs) were used in the analyses.
5. Results
One hundred patients with cirrhosis had a VCE study be-
tween 2010 and 2016. The mean age of the cohort was
62.82±2 years and the mean/MELD score was 13.86±0.66.
Male gender was predominant with 64% of the cohort while
the Caucasians represented 82% (Table 1).Themost common
etiologies of the cirrhosis in our cohort were chronic alcohol
abuse followed by chronic hepatitis C virus (HCV) and non-
alcoholic steatohepatitis (NASH) with percentages of 37%,
22%, and 18%, respectively (Figure 1).
Small intestine evaluation by VCE detected small intesti-
nal lesions in 71% of the patients while 29% patients had
normal study. The features of PHE were found in 65% of
the cohort. Vascular lesions were found in 43% of the cohort
and inflammatory lesions were found in 33%. 11 patients were
found to have more than one type of PHE types with vascular
lesions comprising more than 50% of the PHE lesions. AVMs
and inflammatory changes were the most common findings,
followed by bleeding with percentages of 18%, 18%, and 15%,
respectively (Figure 2).
Our cohort hadmore decompensated cirrhosis defined by
CTP B and C than compensated cirrhosis which is defined as
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Table 1: Demographic MELD: model for end-stage liver disease.
Demographic Number & (%)
Total number of patients 100
Age 62.82±2
MELD score 13.86(±0.66)
Demographics:
Male 64(64%)
Female 36(36%)
Whites 82(82%)
Asian 2(2%)
African-American 1(1%)
Others 15(15%)
Causes of cirrhosis
37%
18%
8%
22%
1%
2%
Congestive Hepatopathy
Cryptogenic
HCV
Alcohol
Hemochromatosis
NASH
PSC
PBC
AIH
Figure 1: Causes of cirrhosis. HCV: hepatitis C virus, NASH: non-
alcoholic steatohepatitis, PSC: primary sclerosing cholangitis, PBC:
primary biliary cirrhosis, and AIH: autoimmune hepatitis.
CTPA. Decompensated cirrhosis (CTP B and C) represented
54% of the cohort while compensated cirrhosis (CTP A)
represented 46% of the cohort.
When the two groups were compared, compensated cir-
rhosis versus decompensated cirrhosis, our data showed that
the risk of having PHE in decompensated cirrhosis (CTP B
and C) is two times the risk in compensated cirrhosis with an
odd ratio of 2 and P-value of 0.01. Our study found that there
was no correlation between thrombocytopenia and PHE.The
risk of PHE is double that in patients with thrombocytopenia
when compared with patients with normal platelet count but
did not reach statistically significant value with P-value 0.09
(Table 2).
There was no correlation between the presence of PHE
and patients’ gender in this study. In addition, there was no
correlation between the etiology of cirrhosis and PHE. We
evaluated the correlation between PHE and other endoscopic
features of portal hypertension like esophageal varices, por-
tal hypertension gastropathy, and gastric varices. Of the 45
Video capsule endoscopy ﬁndings
AVM 18%
Bleeding 15%
Mild Inflammatory 18%
No PHE 35%
Varices 1%
Red spot 9%
Severe Inﬂammatory 15%
11 patients had 2 or more ﬁndings
Figure 2: Video capsule endoscopy findings.
Table 2: The predictor factors of PHE. CTP-A: Child-Turcotte-
Pugh score A, CTP-B+C: Child-Turcotte-Pugh score B and C, HCV:
hepatitis C virus, NASH: nonalcoholic steatohepatitis, PSC: primary
sclerosing cholangitis, PBC: primary biliary cirrhosis, EV: esopha-
geal varices, PHG: portal hypertension gastropathy, GV: gastric vari-
ces, PHE: portal hypertension enteropathy, and OR: odd ratio.
Predictor factors Number PHE No PHE OR P-value
CTP-A 46 26 20 0.5 0.01
CTP-B+C 54 39 15 2.0 0.01
Alcohol 37 20 17 0.4 0.04
HCV 22 13 9 0.4 0.02
NASH 18 14 4 2.1 0.1
Cholestatic liver
disease (PSC+PBC) 8 6 2 1.6 0.4
Thrombocytopenia 69 48 21 1.8 0.09
Male 64 42 22 1.1 0.7
Female 36 23 13 0.9 0.7
EGD + (EV, PHG, or
GV)
55 34 21 0.7 0.5
EGD - 45 31 14 1.3 0.5
patients which had negative EGD exam for any esophageal
varices (EV), portal hypertensive gastropathy (PHG), or gas-
tric varices (GV), 31 patients (69%) had features of portal hy-
pertension enteropathy in their VCE. 55 patients had features
of portal hypertension through the EGD exam including EV,
portal hypertension gastropathy, or gastric varices, and 34
of them (61%) had PHE. Our study also showed that the
presence of PHE does not correlate with the presence or the
absence of the EV, portal hypertension gastropathy, or gastric
varices in cirrhotic patients (Table 2).
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6. Discussion
The features of portal hypertension in the small intestine
vary from normal mucosa to bleeding ectopic varices that
can lead to death. It can involve any part of the gastrointes-
tinal tract: esophageal varices, gastropathy, small intestine en-
teropathy, and/or colopathy [11]. Historically, the first article
describing portal hypertension features in the small intestine
was reported by Jonas et al. who studied those changes in rats.
They described portal hypertension enteropathy as changes
in the small intestinal mucosa that includes erythema, de-
creased duodenal villous perfusion, and an increased suscep-
tibility to injuries [12].
The features of portal hypertension enteropathy were first
described endoscopically byThiruvengadam as an erythema-
tous change in the small intestinal mucosa that resembled
the features of gastropathy and both changes had been called
portal hypertension gastroenteropathy [13].The introduction
of video capsule endoscopy and small intestine enteroscopy
devices helped in better estimating the prevalence of PHE.
More data was published in the last decade describing the
features of the portal hypertension enteropathy (PHE). Most
of these published reports as mentioned above classified
the PHE into two categories: vascular lesions (arteriovenous
malformation (AVM), red spots, bleeding, and varices) and
inflammatory lesions (mild: erosions, erythema or severe: ed-
ema, congested, granular, and friable mucosa) [6, 7, 10].
Most of the information that we have about PHE is from
relatively small size studies, both retrospective and prospec-
tive. These studies estimated the prevalence to have a wide
range between 18% and 100% but the majority of these studies
specially the one with large sample size have a narrower range
of 65% to 69% [8].Our cohort is the largest cohort study in the
USA including 100 cirrhotic patients showing that the preva-
lence of the PHE is 65%, which is similar to the previously
published reports [5–8]. Vascular lesions were detected more
than the inflammatory lesions with percentages of 43% and
33%, respectively.
We found no association between the PHE and the age,
gender, and the etiology of cirrhosis which is similar to the
findings of other published studies. The association of PHE
and the presence of esophageal varices and/or portal hyper-
tension gastropathy was documented by both Goulas et al.
and Aoyama et al. [11, 14]. This association was found to be
in accordance with a study reported byDe Palma et al., which
showed a strong association between the portal hypertension
enteropathy with larger esophageal varices, portal hyperten-
sion, gastropathy, and colopathy.
In our study, 45 patients had a negative EGD study for any
active bleeding or signs of portal hypertension: esophageal
varices, gastric varices, or portal hypertension gastropathy.
Thirty-one of them (67%) had features of portal hypertension
enteropathy in their VCE evaluation of the small intestine.
Therefore, no association was found between the PHE and
EV, portal hypertension gastropathy, or gastric varices.
The prevalence of each type of PHE is different between
the published studies. The prevalence of vascular types of
PHE like AVMs, red spots, and varices ranged within 24%-
55%, 22%-62%, and 8%-38%, respectively [9, 15]. In our
study, the prevalence is lower than the published studies: the
prevalence of the vascular AVMs, red spots, and varices was
18%, 15%, and 1%, respectively.
The reported prevalence of inflammatory lesions ranges
between 5% and 13% [9, 10, 16, 17]. Our cohort had a higher
prevalence of mild and severe inflammatory changes of 15-
18%, respectively.
The correlation between PHE and the liver function
demonstrated by Child-Turcotte-Pugh (CTP) classification is
still controversial. The Child-Pugh classification system takes
into consideration the synthetic function of the liver (albu-
min, INR, and bilirubin) and the clinical presentations of
the portal hypertension (ascites and hepatic encephalopathy).
Misra et al., Alessandro et al., Pennazio et al., and Goulas et
al. found that there is no association between the CTP score
and the presence of PHE [14, 16–18].
In contrast, Aoyama et al. found that PHE is associated
with higher CTP score [11]. De Palma et al. and Abdulaal et
al. both confirmed the association between PHE and the CTP
score as a linear correlation [6, 10]. Our study supports that
correlation as we found a strong association between the CTP
score and the presence of PHE. The risk of having PHE in
decompensated cirrhosis is twice the risk in the compensated
cirrhosis with an odd ratio of 2.0 with CI 95% (P<0.05).
The absence of the features of portal hypertension in
the esophagus and stomach did not exclude the presence of
PHE.Therefore, the absence of association between PHE and
portal hypertension features in the stomach and esophagus
should not preclude the evaluation of the small intestine as
source of bleeding in the cirrhotic patient and VCE might be
warranted regardless the existence of gastroesophageal portal
hypertension features.
These findings provide further insight to the role of the
VCE that can assess in management of these populations,
though our study has its limitation, being a single center,
being retrospective in design, and including a high percent-
age of Caucasians, but it is the first to evaluate such findings
in cirrhotic patients.
7. Conclusion
We conclude that one-third of cirrhotic patients with sus-
pect GI bleed/anemia have treatable PHE lesions. AVMs,
varices, and bleeding lesions are all treatable lesions that can
be evaluated by video capsule endoscopy and treated by
small bowel enteroscopy, single balloon enteroscopy, double
balloon enteroscopy, or trans-jugular intrahepatic-portosys-
temic shunting. Hepatologists and gastroenterologists should
not be hesitant to pursue this investigative modality in this
population, when no active bleeding is found by traditional
EGD and colonoscopic evaluation.
8. Summary
Portal hypertension enteropathy is prevalent in cirrhotic
patient and carries the risk of obscure GI bleeding. The pub-
lished data regards the small samples sizes which suggested
the prevalence, and our cohort, the largest cohort in the
US, supported the previous facts. Our data supports the fact
that PHE was associated with decompensated cirrhosis. The
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absence of varices in the stomach or esophagus should not
distract the gastroenterologist from further investigating the
small intestine for features of portal hypertension.
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